Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903078 | 1.00 | HDAC8 (0.43) | HDAC8HDAC6ROCK2MCHR1DDB1 | |
| SCHEMBL26329071 | 0.83 | MCHR1 (0.44) | HDAC8HDAC6ROCK2MCHR1 | |
| SCHEMBL20595486 | 0.79 | HTR2C (0.42) | — | |
| SCHEMBL31108082 | 0.79 | HTR2C (0.42) | — | |
| SCHEMBL23702952 | 0.71 | HDAC8 (0.49) | HDAC8HDAC6ROCK2MCHR1DDB1 | |
| SCHEMBL26772947 | 0.71 | HDAC8 (0.49) | HDAC8HDAC6ROCK2MCHR1DDB1 | |
| SCHEMBL20595416 | 0.70 | NPC1 (0.42) | — | |
| SCHEMBL21965434 | 0.70 | SLC6A4 (0.41) | GRM5 | |
| SCHEMBL22119554 | 0.67 | RAB9A (0.52) | HDAC6 | |
| SCHEMBL9407245 | 0.66 | HDAC8 (0.52) | HDAC8HDAC6ROCK2MCHR1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | HDAC8 3091/4885HDAC6 2941/4885ROCK2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.